Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis
Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the ex...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Grenga, Italia [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2018transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
8381 |
|---|
| Übergeordnetes Werk: |
Enthalten in: BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex - Siero, Jeroen C.W. ELSEVIER, 2014transfer abstract, Amsterdam [u.a.] |
|---|---|
| Übergeordnetes Werk: |
volume:36 ; year:2018 ; number:3 ; pages:931-9311 ; extent:8381 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.urolonc.2017.09.027 |
|---|
| Katalog-ID: |
ELV042118514 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV042118514 | ||
| 003 | DE-627 | ||
| 005 | 20230626000555.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180726s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.urolonc.2017.09.027 |2 doi | |
| 028 | 5 | 2 | |a GBV00000000000276A.pica |
| 035 | |a (DE-627)ELV042118514 | ||
| 035 | |a (ELSEVIER)S1078-1439(17)30524-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Grenga, Italia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| 264 | 1 | |c 2018transfer abstract | |
| 300 | |a 8381 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. | ||
| 520 | |a Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. | ||
| 650 | 7 | |a Immunogenic modulation |2 Elsevier | |
| 650 | 7 | |a Anti-PD-L1 |2 Elsevier | |
| 650 | 7 | |a TGFβ |2 Elsevier | |
| 650 | 7 | |a Antibody-dependent cellular cytotoxicity |2 Elsevier | |
| 650 | 7 | |a Bladder cancer |2 Elsevier | |
| 650 | 7 | |a CTL-mediated lysis |2 Elsevier | |
| 700 | 1 | |a Donahue, Renee N. |4 oth | |
| 700 | 1 | |a Gargulak, Morgan L. |4 oth | |
| 700 | 1 | |a Lepone, Lauren M. |4 oth | |
| 700 | 1 | |a Roselli, Mario |4 oth | |
| 700 | 1 | |a Bilusic, Marijo |4 oth | |
| 700 | 1 | |a Schlom, Jeffrey |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Science |a Siero, Jeroen C.W. ELSEVIER |t BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |d 2014transfer abstract |g Amsterdam [u.a.] |w (DE-627)ELV012523860 |
| 773 | 1 | 8 | |g volume:36 |g year:2018 |g number:3 |g pages:931-9311 |g extent:8381 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.urolonc.2017.09.027 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2018 |e 3 |h 931-9311 |g 8381 |y 36.2018, 3, 93.e1-, (8381 S.) | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
i g ig |
|---|---|
| matchkey_str |
grengaitaliadonahuereneengargulakmorganl:2018----:nid1grm84uinrtiidcsmuoeimdltoohmnrteilacnmcllnsedrntemrsse |
| hierarchy_sort_str |
2018transfer abstract |
| publishDate |
2018 |
| allfields |
10.1016/j.urolonc.2017.09.027 doi GBV00000000000276A.pica (DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Grenga, Italia verfasserin aut Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 2018transfer abstract 8381 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier Donahue, Renee N. oth Gargulak, Morgan L. oth Lepone, Lauren M. oth Roselli, Mario oth Bilusic, Marijo oth Schlom, Jeffrey oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:36 year:2018 number:3 pages:931-9311 extent:8381 https://doi.org/10.1016/j.urolonc.2017.09.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 36 2018 3 931-9311 8381 36.2018, 3, 93.e1-, (8381 S.) 045F 610 |
| spelling |
10.1016/j.urolonc.2017.09.027 doi GBV00000000000276A.pica (DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Grenga, Italia verfasserin aut Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 2018transfer abstract 8381 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier Donahue, Renee N. oth Gargulak, Morgan L. oth Lepone, Lauren M. oth Roselli, Mario oth Bilusic, Marijo oth Schlom, Jeffrey oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:36 year:2018 number:3 pages:931-9311 extent:8381 https://doi.org/10.1016/j.urolonc.2017.09.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 36 2018 3 931-9311 8381 36.2018, 3, 93.e1-, (8381 S.) 045F 610 |
| allfields_unstemmed |
10.1016/j.urolonc.2017.09.027 doi GBV00000000000276A.pica (DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Grenga, Italia verfasserin aut Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 2018transfer abstract 8381 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier Donahue, Renee N. oth Gargulak, Morgan L. oth Lepone, Lauren M. oth Roselli, Mario oth Bilusic, Marijo oth Schlom, Jeffrey oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:36 year:2018 number:3 pages:931-9311 extent:8381 https://doi.org/10.1016/j.urolonc.2017.09.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 36 2018 3 931-9311 8381 36.2018, 3, 93.e1-, (8381 S.) 045F 610 |
| allfieldsGer |
10.1016/j.urolonc.2017.09.027 doi GBV00000000000276A.pica (DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Grenga, Italia verfasserin aut Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 2018transfer abstract 8381 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier Donahue, Renee N. oth Gargulak, Morgan L. oth Lepone, Lauren M. oth Roselli, Mario oth Bilusic, Marijo oth Schlom, Jeffrey oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:36 year:2018 number:3 pages:931-9311 extent:8381 https://doi.org/10.1016/j.urolonc.2017.09.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 36 2018 3 931-9311 8381 36.2018, 3, 93.e1-, (8381 S.) 045F 610 |
| allfieldsSound |
10.1016/j.urolonc.2017.09.027 doi GBV00000000000276A.pica (DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ Grenga, Italia verfasserin aut Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis 2018transfer abstract 8381 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier Donahue, Renee N. oth Gargulak, Morgan L. oth Lepone, Lauren M. oth Roselli, Mario oth Bilusic, Marijo oth Schlom, Jeffrey oth Enthalten in Elsevier Science Siero, Jeroen C.W. ELSEVIER BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex 2014transfer abstract Amsterdam [u.a.] (DE-627)ELV012523860 volume:36 year:2018 number:3 pages:931-9311 extent:8381 https://doi.org/10.1016/j.urolonc.2017.09.027 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U AR 36 2018 3 931-9311 8381 36.2018, 3, 93.e1-, (8381 S.) 045F 610 |
| language |
English |
| source |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:36 year:2018 number:3 pages:931-9311 extent:8381 |
| sourceStr |
Enthalten in BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex Amsterdam [u.a.] volume:36 year:2018 number:3 pages:931-9311 extent:8381 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
Immunogenic modulation Anti-PD-L1 TGFβ Antibody-dependent cellular cytotoxicity Bladder cancer CTL-mediated lysis |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| authorswithroles_txt_mv |
Grenga, Italia @@aut@@ Donahue, Renee N. @@oth@@ Gargulak, Morgan L. @@oth@@ Lepone, Lauren M. @@oth@@ Roselli, Mario @@oth@@ Bilusic, Marijo @@oth@@ Schlom, Jeffrey @@oth@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
ELV012523860 |
| dewey-sort |
3610 |
| id |
ELV042118514 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042118514</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626000555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.09.027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000276A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042118514</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30524-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Grenga, Italia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8381</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenic modulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGFβ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibody-dependent cellular cytotoxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bladder cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTL-mediated lysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Donahue, Renee N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gargulak, Morgan L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lepone, Lauren M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roselli, Mario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bilusic, Marijo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlom, Jeffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:931-9311</subfield><subfield code="g">extent:8381</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.09.027</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">931-9311</subfield><subfield code="g">8381</subfield><subfield code="y">36.2018, 3, 93.e1-, (8381 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Grenga, Italia |
| spellingShingle |
Grenga, Italia ddc 610 Elsevier Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| authorStr |
Grenga, Italia |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV012523860 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis Elsevier |
| topic |
ddc 610 Elsevier Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis |
| topic_unstemmed |
ddc 610 Elsevier Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis |
| topic_browse |
ddc 610 Elsevier Immunogenic modulation Elsevier Anti-PD-L1 Elsevier TGFβ Elsevier Antibody-dependent cellular cytotoxicity Elsevier Bladder cancer Elsevier CTL-mediated lysis |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
r n d rn rnd m l g ml mlg l m l lm lml m r mr m b mb j s js |
| hierarchy_parent_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| hierarchy_parent_id |
ELV012523860 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV012523860 |
| title |
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| ctrlnum |
(DE-627)ELV042118514 (ELSEVIER)S1078-1439(17)30524-0 |
| title_full |
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| author_sort |
Grenga, Italia |
| journal |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| journalStr |
BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
zzz |
| container_start_page |
931 |
| author_browse |
Grenga, Italia |
| container_volume |
36 |
| physical |
8381 |
| class |
610 610 DE-600 610 VZ |
| format_se |
Elektronische Aufsätze |
| author-letter |
Grenga, Italia |
| doi_str_mv |
10.1016/j.urolonc.2017.09.027 |
| dewey-full |
610 |
| title_sort |
anti-pd-l1/tgfβr2 (m7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| title_auth |
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| abstract |
Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. |
| abstractGer |
Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. |
| abstract_unstemmed |
Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| container_issue |
3 |
| title_short |
Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis |
| url |
https://doi.org/10.1016/j.urolonc.2017.09.027 |
| remote_bool |
true |
| author2 |
Donahue, Renee N. Gargulak, Morgan L. Lepone, Lauren M. Roselli, Mario Bilusic, Marijo Schlom, Jeffrey |
| author2Str |
Donahue, Renee N. Gargulak, Morgan L. Lepone, Lauren M. Roselli, Mario Bilusic, Marijo Schlom, Jeffrey |
| ppnlink |
ELV012523860 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth |
| doi_str |
10.1016/j.urolonc.2017.09.027 |
| up_date |
2024-07-06T21:57:19.513Z |
| _version_ |
1803868479961432064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV042118514</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230626000555.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180726s2018 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.urolonc.2017.09.027</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBV00000000000276A.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV042118514</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1078-1439(17)30524-0</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Grenga, Italia</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Anti-PD-L1/TGFβR2 (M7824) fusion protein induces immunogenic modulation of human urothelial carcinoma cell lines, rendering them more susceptible to immune-mediated recognition and lysis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">8381</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Avelumab has recently been approved by the Food and Drug Administration for the therapy of Merkel cell carcinoma and urothelial carcinoma. M7824 is a novel first-in-class bifunctional fusion protein comprising a monoclonal antibody against programmed death-ligand 1 (PD-L1, avelumab), fused to the extracellular domain of human transforming growth factor beta (TGFβ) receptor 2, which functions as a TGFβ “trap.” Advanced urothelial tumors have been shown to express TGFβ, which possesses immunosuppressive properties that promote cancer progression and metastasis. The rationale for a combined molecule is to block the PD-1/PD-L1 interaction between tumor cells and immune cell infiltrate and simultaneously reduce or eliminate TGFβ from the tumor microenvironment. In this study, we explored the effect of M7824 on invasive urothelial carcinoma cell lines.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Immunogenic modulation</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Anti-PD-L1</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">TGFβ</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antibody-dependent cellular cytotoxicity</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Bladder cancer</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">CTL-mediated lysis</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Donahue, Renee N.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gargulak, Morgan L.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Lepone, Lauren M.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Roselli, Mario</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bilusic, Marijo</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Schlom, Jeffrey</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Science</subfield><subfield code="a">Siero, Jeroen C.W. ELSEVIER</subfield><subfield code="t">BOLD matches neuronal activity at the mm scale: A combined 7T fMRI and ECoG study in human sensorimotor cortex</subfield><subfield code="d">2014transfer abstract</subfield><subfield code="g">Amsterdam [u.a.]</subfield><subfield code="w">(DE-627)ELV012523860</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:931-9311</subfield><subfield code="g">extent:8381</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.urolonc.2017.09.027</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">2018</subfield><subfield code="e">3</subfield><subfield code="h">931-9311</subfield><subfield code="g">8381</subfield><subfield code="y">36.2018, 3, 93.e1-, (8381 S.)</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.4005365 |